News
Laverock Therapeutics raises £13.5m to develop unique gene silencing platform for programmable advanced therapies
Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications, has expanded its seed...
LEQEMBI Intravenous Infusion approved in Japan as treatment for slowing progression of mild cognitive...
Eisai and Biogen's humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a...
US FDA approves Jardiance to treat adults with chronic kidney disease
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly and Company's Jardiance (empagliflozin) 10 mg tablets to reduce the...
